)
Edge26 Jun 2026
The Universal Language: Inventing the Barcode
How lines in the sand on a Miami beach became the most scanned symbol in human history, and why it took decades for anyone to care.
Indaptus Therapeutics
Indaptus Therapeutics (INDP) investor relations material
Indaptus Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary26 Jun, 2026
Company overview and business model
Clinical-stage biotechnology company focused on systemically-administered anti-cancer and anti-viral immunotherapies using attenuated, killed Gram-negative bacteria to activate innate and adaptive immunity.
Lead candidate Decoy20 completed Phase 1 monotherapy and combination studies in advanced solid tumors; all clinical development paused pending strategic review and financing.
Recent focus shifted to evaluating strategic alternatives, including potential transactions, collaborations, or acquisitions, and limited nonclinical research initiatives.
Financial performance and metrics
Multiple financings completed from August 2024 to June 2026, including direct offerings, private placements, convertible notes, and an equity line, raising over $20 million gross.
Implemented a 1-for-28 reverse stock split effective June 26, 2025.
Auditor's report expresses substantial doubt about ability to continue as a going concern.
Use of proceeds and capital allocation
No proceeds will be received from the resale of 18,864,000 shares by selling stockholders; all proceeds go to selling stockholders.
Company has historically used proceeds for R&D, clinical trials, and general corporate purposes.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Indaptus Therapeutics
- Key votes include director elections, auditor ratification, a new equity plan, and a major share issuance.INDP
Proxy filing22 Jun 2026 - Q2 net loss widened to $4.0M; cash runway extends into Q1 2025 amid ongoing funding risks.INDPQ2 20248 Jun 2026
- Cash runway into Q1 2025 amid narrowed losses and clinical progress, but urgent funding needed.INDPQ3 20248 Jun 2026
- Decoy20 Phase 1 trial reached key milestone; FY 2024 net loss narrowed, cash runway into Q2 2025.INDPQ4 20248 Jun 2026
- Q1 2025 net loss rose to $4.53M; cash runway short, new funding needed for Decoy20 combo trial.INDPQ1 20258 Jun 2026
- Net loss rose to $5.2M as R&D spending increased; $5.7M raised; cash runway into Q4 2025.INDPQ2 20258 Jun 2026
- Q3 2025 net loss was $3.0M; cash runway into Q1 2026; trial paused for efficacy review.INDPQ3 20258 Jun 2026
- Net loss narrowed to $2.5M, but urgent capital is needed as cash reserves dwindle.INDPQ1 20268 Jun 2026
- Decoy20 immunotherapy shows early safety and immune activation, with pivotal data expected in 2025.INDPInvestor presentation8 Jun 2026
Next Indaptus Therapeutics earnings date
Q2 202614 Aug, 2026
Indaptus Therapeutics
Next Indaptus Therapeutics earnings date
Q2 202614 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage